National registry for patients with Multiple Myeloma in Germany
Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)
This study is tracking patients with Multiple Myeloma in Germany for up to five years to see how their disease progresses and how different treatments affect their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | iOMEDICO AG Industry-sponsored |
| Locations | 1 site (Multiple Sites) |
| Trial ID | NCT03308474 on ClinicalTrials.gov |
What this trial studies
MYRIAM is a national, observational, prospective, longitudinal cohort study designed to document uniform data on the characteristics, molecular diagnostics, treatment, and disease progression of patients with Multiple Myeloma in Germany. The study will follow patients for up to five years, collecting data on patient characteristics, comorbidities, tumor characteristics, and previous treatments. It aims to identify common therapeutic sequences and changes in treatment, while also evaluating health-related quality of life through patient-reported outcomes. A decentralized biobank will be established to support future research.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with Multiple Myeloma requiring systemic treatment.
Not a fit: Patients who are not undergoing systemic therapy for Multiple Myeloma or are already enrolled in conflicting studies may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of Multiple Myeloma treatment patterns and improve patient outcomes through better-informed clinical practices.
How similar studies have performed: Other observational studies and registries have shown success in improving treatment understanding and patient outcomes in similar conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment) * Age ≥ 18 years * Written informed consent * Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment * Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment * Sufficient German language skills for participation in the PRO satellite Exclusion Criteria: * No systemic therapy for myeloma * Patients already enrolled in studies that prohibit any participation in other studies
Where this trial is running
Multiple Sites
- Multiple sites all over germany — Multiple Sites, Germany (Recruiting)
Study contacts
- Study coordinator: Martina Jänicke, PhD
- Email: info@iomedico.de
- Phone: +49 761 15242-0
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.